T lymphocytes and a subpopulation of B lymphocytes express the CD5 co-receptor. Its functional importance is evident from the multiple levels and developmental stages of the regulation of its expression. We report the discovery of a novel regulatory exon upstream of the non-coding region of the cd5 gene in humans. This alternate exon 1 is designated E1B (with the conventional exon 1 renamed E1A), and shown to regulate the expression of CD5. E1B-containing transcripts exist exclusively in B lymphocytes, encode a protein which is truncated, and retained intracellularly. As a consequence, the amount of E1A-containing transcripts is down-regulated, and the membrane CD5 expression diminished in the presence of E1B-containing transcripts.
Originally thought to be exclusive to T cells, the CD5 marker distributes B lymphocytes into 2 compartments 1 : CD5 -or B2 cells, and CD5 + or B-1 cells. The latter are subdivided into B-1a that carry CD5, and B-1b that do not, but share other attributes of B-1a cells. B-1a lymphocytes lie at the crossroads of oncology since chronic lymphocytic leukemia (CLL) cells carry CD5, 2 and immunology since leukemic patients display autoimmune phenomena. 3 CD5 cross-linking influences antigen (Ag) receptor-mediated signaling, and based on findings in CD5-deficient mice, 4 its effect on B cell receptor (BCR)-mediated signaling is negative 5 through the association of CD5 6 with the SH2-containing phosphatase 1 (SHP-1).
The expression of CD5 is tightly controlled. Its membrane density is ~30-fold higher in T cells than in B cells. 7 Given the higher membrane density of CD5 on mature T lymphocytes than on thymocytes, 8 its expression is regarded as developmentally regulated. Furthermore, B-1a cells represent the majority of B lineage cells during neonatal life, but decline thereafter. In addition, when cultured in the presence of interleukin (IL)-4, B cells reduce their CD5 expression, whereas this is raised by phorbol myristic acetate (PMA), or cross-linking IgM in the presence of IL-6. 9 A nu-population. 15 Thus, regulatory mechanisms for CD5 expression exist in the mouse, but far less is known in humans.
Understanding this modulation will help us to gain insights into the functional relevance of CD5. This glycoprotein is encoded by a single gene in T and B
lymphocytes, that maps to chromosome 11q12.2 in humans, 16 and consists of 11 exons. The level at which the cd5 gene is regulated remains elusive, although conserved in size and organization. Numerous transcription factors have thus far been characterized.
This investigation set out to examine mechanisms of CD5 expression in human lymphocytes. We report the discovery of an exon 1 that is exclusively transcribed in B lymphocytes, and due to the integration of a human endogenous retrovirus (HERV) into the cd5 locus. Our data also provide evidence for a reciprocal expression of the alternative exon 1, designated E1B, with the conventional exon 1 renamed E1A.
E1B transcripts are translated into a truncated isoform of the CD5 molecule devoid of the leader peptide. Consequently, products of E1B transcripts are not translocated to the membrane, but down-regulate membrane CD5 expression. This precludes the SHP-1-related signal inhibiting functions of CD5, and induces antibody (Ab) production. A balance between the 2 alternative exons 1 might be central to the regulation of membrane CD5 in human B cells.
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MATERIALS AND METHODS

Cellular protocols
B lymphocytes were isolated from tonsil single-cell suspensions, from cord bloods (CB), and from healthy volunteer or CLL patient peripheral blood mononuclear cells (PBMCs), by centrifugation on Ficoll-Hypaque, followed by 2 rounds of rosetting with sheep erythrocytes, and positive selection with anti-CD19-coated magnetic microbeads (Miltenyi, Bergisch Gladbach, Germany). T lymphocytes were isolated using anti-CD3-coated microbeads. Purity of B and T lymphocytes was verified by FACS analysis using FITC-anti-CD19 or FITC-anti-CD3 monoclonal Abs (mAbs), with phycoerythrin (PE)-anti-CD5 (Beckman-Coulter, Villepinte, France). All B and T lymphocyte preparations were >99% pure CD19 + , and CD3 + cells, respectively. 
Setting and ethical approval
The study protocol was approved by the institutional review board of Brest, France, and informed consent of patients was obtained according to the declaration of Helsinki.
Fluorescence-activated cell sorter analysis
Cell preparations were adjusted to 5x10 5 
Rapid amplification of cDNA
The 5' transcript ends were amplified using 1µg of mRNA, and SMART-RACE of cDNA performed using a kit (Clontech, Palo Alto, CA). The first strand of cDNA was synthesized using SMART IIA oligonucleotide and 5'RACE cDNA synthesis primer, and 5'RACE PCR performed using the sense UPM primer and the genespecific antisense primer CD5 E5-6 with the Advantage 2 polymerase. The Touchdown-PCR protocol included denaturation at 94°C for 5 minutes, starting 5 touchdown-PCR cycles of denaturation at 94°C for 30 seconds, and annealing at 72°C for 3 minutes. These were completed by another 5 cycles (denaturation at 94°C for 30 seconds, annealing at 70°C for 1 minute and primer extension at 72°C for 3 minutes). Another 40 cycles consisted of denaturation at 94°C for 30 seconds, annealing at 68°C for 1 minute and primer extension at 72°C for 3 minutes. The products were subcloned using the pTrueBlue ligation kit (Genomics One Corporation, Laval, Canada), and sequenced using the BigDye Terminator Cycle Sequencing Kit and the ABI-310 Genetic Analyzer (Applied Biosystems, Foster City, CA).
Reverse transcriptase-PCR for cd5 gene regulatory elements
One µg of mRNA was extracted by the RNAble method (Eurobio), transcribed with reverse transcriptase (RT) and oligo-dT, and used for PCR amplification with either CD5-, CD3 -, CD79b-, or GAPDH-specific primers (GenBank sequences: X04391, NM000 734, M80461 and BC014085, respectively). CD3 and CD79b am- cDNA was separated on 2% agarose gel, and visualized with 0.5µg/ml ethidium bromide. The PCR products were checked by sequencing, and digestions with Bam HI (E1B), Acc I (exon 3) or Kpn I (exon 5). Band densities were evaluated using Molecular Analyst software (BioRad), and the mean OD for each point was calculated.
Quantitative RT-PCR
Quantitative PCR was performed in 10µL mixtures containing 50ng template cDNA, 500nM of each primer, 1X SYBR Green PCR Master mix (Applied Biosystems). Each assay included the reaction mixture with no template as a negative control, and GAPDH mRNA as a positive control. Standard curves were constructed using the same PCR mixtures with 10 4 -10 7 copies/mL of mRNA from the cd5 gene insert in pTrueBlue. Numbers of CD5 transcript copies were inferred from the threshold cycle numbers, and the standard curves normalized to GAPDH values. Results were exported as Tab-delimited text files and imported into Microsoft® Excel. 
Expression of the CD5 protein product in rabbit reticulocytes
We used a TnT® T7-Coupled Reticulocyte Lysate System (Promega, Charbonnières, France) for in vitro translation of cd5 transcripts. This kit supplied rabbit reticulocyte lysate, T7 RNA polymerase, and a mixture of amino acids (aa). The 10µL mixtures were made up of biot-lysine, 200ng of plasmid DNA, pDNR, with the cd5 gene insert. A pDNR plasmid without an insert was the negative control, and a plasmid containing the 61-kD luciferase gene the positive control. The mixtures were incubated for 2 hours at 30°C, and proteins separated by 5-20% SDS-PAGE and transferred onto PVDF membranes which were stained with streptavidin-HRP, and revealed by ECL.
Transient transfection
COS-1 cells were plated out at 10 6 cell/well in DMEM, and cultured until they EDTA, 140mM NaCl, 1% Triton X-100, 0.5mM PMSF, 1µM aprotinine, 3µg/mL leupeptine and 1µg/mL pepstatine). Its protein content was evaluated by Western blotting (WB), using an HRP-anti-GFP Ab.
Establishment of CD5-1B-expressing cell lines
Using the same method, Jurkat T cells were transfected with the pLP cmv, with or without the full-length CD5-1B cDNA. Vector-containing lymphocytes were selected with G418 (Sigma). The CD5 low cells were sorted from the pLP cmv, and the pLP-CD5-1B populations and placed in culture. After 7 days, they were FACSanalyzed with PE-anti-CD5 UCHT2. Cell extracts were also resolved by SDS-PAGE, and probed with anti-CD5 Leu1. CD5-1A and CD5-1B mRNAs were quantified in pLP cmv and pLP-CD5-1B cells by quantitative PCR.
In situ hybridization
For the in situ hybridization, oligonucleotide primers were labeled with digoxigenin (dig) at the 3' ends, using 50U terminal transferase (Roche, Meylan, France).
The cells were resuspended at 2x10 6 /mL in HBSS, and 10 5 cells attached to slides, dried at 25°C, and fixed with 4% p-formaldehyde.
Tonsil sections were de-paraffinized and re-hydrated. Cells and sections were permeabilized with 0.1% Triton X-100, and dehydrated. The slides were re-hydrated, air-dried, treated with proteinase K incubated in the hybridization buffer (50% formamide, 2X SSC, 1X Denharts, 10% dextran sulfate, 150µg/mL tRNA, 100µg/mL polyA, 100µg/mL single-stranded DNA) for 1 hour at 37°C, and incubated overnight at 37°C
in the same buffer completed with 200µl/mL of the dig primers. They were washed with a 2X SSC, 0.1% SDS, followed by 1X and 0.5X SSC, and incubated in 1X Roche
Blocking Reagent for 30 minutes, and with alkaline phosphatase F(ab') 2 anti-dig Ab (Roche) overnight at 25°C. Probes were localized by NBT/5-bromo-4-chloro-3-indolyl phosphate.
Sequence analyses
The sequence of the cd5 gene-containing clone CMB9-39H21 (GenBank No.
AC000437) was identified using BLAST searches with the cd5 cDNA sequence (Genbank No. X89405, X04391). Data bases and sequences were analyzed using DNasis software package and Networks service.
Production of recombinant CD5 vectors
The full-length cd5 cDNA clone extended from the known ATG1 initiation site at position -8129 to the stop codon at position +23550 in E11 of the genomic sequence of cd5 gene. It was generated by RT-PCR, using a sense primer for the -8129/-8105 region, and an antisense primer downstream of the stop codon (Table 1) . Amplifications used a mixture of Pwo and Taq polymerases, and PCR products were subcloned into pTrueBlue vector (Genomics One). To generate CD5-1BpDNR dual, some of these were subcloned into pDNRdual which has a T7 promoter for transcription in reticulocytes. The rest was subcloned into the pLP cmv vector using the Crerecombinase system (Clontech), or served to generate fusion proteins with GFP. They were modified by PCR using a primer for the T7 promoter in the pTrueBlue, combined with an antisense primer. This anneals to 3' end of the original PCR product, and sub- 
RESULTS
Genetic and database analyses
To identify regulatory regions that modulate CD5 expression, genomic and cDNA sequences of the cd5 gene were analyzed using the GENSCAN and the NIH Web servers. Within the 5' non-coding region, there was a defective HERV gene sequence, starting 8.2 kb upstream of the ATG1 initiation site in exon 1 ( Figure 1A ). This is identifiable based on the gag, pol and env sequences, and long terminal repeats has the potential to splice to the initiation site on other exons of the cd5 gene. We were unable to identify any other sequences that could, potentially, be involved in the regulation of the gene.
To locate E1B, the cDNA of cd5 was mapped using 34 sense primers designed from genomic DNA and spanning regions in the 10kb upstream of E1A and E1B (Figure 1A) . E1A-transcripts were found in both T and B cells, whereas E1B-transcripts were specific for B cells. Restriction digestion patterns were identical to those predicted from the known cDNA sequence, 19 and sequence analysis of E1B fully matched the 5' sequence of the cd5 gene from the data base. A model for independent splicing of E1B to downstream exon 2 is depicted in Figure 1B .
Transcription initiation sites of human cd5 gene in exon 1
To find transcriptional initiation sites of E1B, and demonstrate alternate use of E1A and E1B, 5'-RACE was performed on total mRNA from tonsillar B and T cells (Figure 2A ). The products were subcloned in pTrueBlue plasmid and sequenced. Two types of plasmid products were generated : the known E1A linked with the full-length cd5 cDNA, and the new E1B linked with the cd5 cDNA at an exon 2 site. In these plasmids, E1A was deleted, and replaced with E1B (these sequence data are available from Genbank under accession numbers AY541703 and AY541704, respectively). domain is lacking in the novel CD5 molecule. These studies showed that E1B was expressed in transcripts from B, but not in those from T lymphocytes, and confirmed that the predicted alternative E1B splice site was on exon 2.
E1B is selectively transcribed in B lymphocytes
Primers annealed to E1A, E1B or exon 2, together with an antisense primer specific for the junction between the rearranged exon 5 and exon 6. While the PCR using the 5' E1A primer yielded products in both B and T lymphocytes, the 5' E1B
primer was specific for B lymphocytes ( Figure 2C ). Quantitative PCR confirmed that T cells did not make E1B-transcripts, whereas B cells did. Levels of PCR products were higher with the E1B primer than with the E1A in tonsillar B cells. Interestingly, E1B-containing transcripts were absent in other CD5-nonexpressing cells, such as monocytes, neutrophils and endothelial cells.
To substantiate that transcription of E1B affects the density of surface CD5, B1a, B-1b and B-2 cells were sorted, and E1A-and E1B-transcripts enumerated ( Figure   3A ). The level of E1A was higher in B-1a than in B-1b, and in B-1b than in B-2 cells.
In situ hybridization with one pair of primers specific for E1A-transcripts and another specific for E1B-transcripts circumvented PCR artifacts. Cytospun cells ( Figure 3B) showed that T cells had more E1A-mRNA than B cells, and that T cells did not contain E1B-transcripts. In situ hybridization ( Figure 3C ) placed E1A-transcriptcontaining cells in the T lymphocyte zone and in the follicular mantle area of tonsil sections. In contrast, E1B-transcript-containing cells were not seen in this T lymphocyte zone, but rather in the B lymphocyte follicles and in the follicular mantle.
Effects of cell activation on the expression of E1A and E1B
RT-PCRs of mRNA from T and B cells, before and after activation, explored the functional relevance of the alternative transcription of the two exons 1 ( Figure 4A ).
For
RT-PCR of mRNA from T lymphocytes using the exon 2 and the E1A primers presented characteristic products. Using the E1B primer, no PCR products were obtained from activated T cells, whilst activation of B cells with PMA, anti-IgM or SAC increased PCR products triggered by the E1A primer and the E1B primer.
E1B-containing transcripts in B lymphocyte subpopulations
Were alternate transcripts differentially regulated in B cell subpopulations ? In contrast to tonsillar B lymphocytes which mainly transcribed E1B ( Figures 2C and 3B, and Table 2 ), those from CLL patients expressed more E1A-than E1B-transcripts ( Figure 4B and Table 2 ). We reasoned that such differences might relate to the membrane expression of the molecule, which is increased in CLL B cells. 20 As we reported Table 2 . These data indicate that T lymphocytes have transcripts with E1A but not with E1B, and that mature B lymphocytes express distinct transcripts with either of these exons 1. There was a correlation between the density of membrane CD5 and the amount of E1A-transcripts, the higher the level of membrane CD5 expression, the more E1A-transcripts (p<0.01); and the lower the level of membrane CD5 expression, the more E1B-transcripts (p<0.01). CD5-E1A plus CD5-E1B) was significantly higher in the B-1b than in the B-2 cells.
Nature of CD5 protein encoded by E1B-transcripts
To demonstrate that E1B-type transcripts encode a functional protein, a gene construct containing cDNA from an E1B-type transcript was inserted into the pDNR
plasmid. An insert-lacking pDNR plasmid was the negative control, and a plasmid containing the 61-kD protein-encoding luciferase gene were the negative and the positive controls, respectively. The reticulocyte system produced a 52-kD protein in lysates from the plasmid containing the E1B-type transcript ( Figure 5A ). Based on the mw of the protein product, one may assume that the initiation site of the protein is the distal 5' ATG ( Figure 1B ).
With anti-PY Ab as a positive control ( Figure 5B ), immune precipitation analysis revealed that, whereas anti-CD5 mAb UCHT2 recognized the protein encoded by
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From the E1B-type transcript in the 697 pre-B cells, this was not the case using anti-CD5 mAb Leu1, confirming that 2 distinct isoforms of the CD5 protein exist.
E1B-type transcripts translate into intracellularly retained protein
Our observation that UCHT2 recognizes both CD5 isoforms was exploited to localize these 2 proteins. Analysis of CD5 expression with UCHT2 showed that Jurkat T lymphocytes (which only have E1A-transcripts) strongly expressed membrane CD5 ( Figure 5C ). In contrast, the 697 pre-B cells (which only have E1B-transcripts) did not carry membrane CD5. However, when both cell lines were permeabilized, there was evidence for intracellular CD5 protein in the 697 pre-B cells, albeit at a low level, whilst Jurkat T-cells were similar to non-permeabilized cells.
The results of the intracellular versus membrane expression of the presumed CD5 protein isoforms in the 2 cell lines was confirmed by immunocytochemistry. The CD5 molecules recognized by UCHT2 were expressed on the membrane of Jurkat T cells, but confined to the cytoplasm of 697 pre-B cells ( Figure 5D ).
To confirm that E1B encodes an intracellular isoform of CD5, we fused the cDNA for E1B-type transcripts with the GFP gene, and expressed the recombinant protein. SDS-PAGE analysis showed GFP expression (bottom arrowhead in the left lane of Figure 5E ), and the CD5-E1B-GFP recognized by anti-GFP mAb (top arrowhead on the right lane of Figure 5E ). In addition, COS-1 cells transfected with the construct containing the E1B-transcript and the GFP gene, showed that E1B-containing construct directed intracellular protein synthesis.
Effect of E1B on the membrane expression of CD5
Introduction of CD5-1B cDNA into Jurkat cells reduced the membrane expression of the CD5 protein ( Figure 6A ). This could not be ascribed to a limited transcription of the CD5-1A-containing variant, as established by quantitative PCR ( Figure   6B ). The anti-CD5 mAb Leu1 ( Figure 6C ) did not affect the amount of full-length CD5 protein. Our data suggest that truncated CD5 acts, not to decrease the synthesis of the full-length variant of this protein, but to prevent its translocation to the membrane. Owing to the absence of a leader peptide, E1B-encoded CD5 molecules cannot reach the plasma membrane, as documented by immunohistochemical studies of the 697 pre-B cells that exclusively contain E1B-CD5 protein, and analyses of cells transfected with a construct combining GFP and E1B-cDNA. Hence, differential usage of E1A and E1B regulate synthesis of full-length or truncated isoforms of CD5, and, thereby, its membrane expression level.
While E1A was transcribed in both B and T cells, E1B-transcripts were undetectable in T cells. This result suggests a relationships between the density of membrane CD5 and the amount of E1A-transcripts in the B cells : high quantities of E1A-transcripts were found in CLL cells, which express high levels of membrane CD5 compared with trace amounts in CB and adult B lymphocytes. Further, no E1A-transcripts were found in 697 pre-B cells which have no membrane CD5. In contrast to T lymphocytes, activation of B lymphocytes promoted the transcription of E1A-transcripts, and raised the membrane density of CD5. This observation is consistent with the expression of CD5 following BCR cross-linking, or engagement by Tindependent type 2 Ags. 24 Thus, up-regulation of CD5 may represent a physiological response to attenuate signaling through the BCR-CD5 complex, which is crucial in preventing cells from responding to BCR engagement by self Ag, or being killed by apoptosis. 25 For
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The CD5 expression regulation results from an interplay between several mechanisms. At the post-translational level, shedding of membrane CD5 has been described. 26 CD5 internalization, which is enhanced in T cells, but inhibited in B cells, is another mechanism of differential CD5 regulation. 27 A signal transduction pathway promoting cd5 gene transcription has also been suggested to exist. 28 
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